E14514 Background: Postop chemotherapy ± radiation therapy (CRT) is standard for US patients (pts) with resected pancreatic cancer (PC). Neoadjuvant advantages include timely systemic treatment and optimal pt selection for surgery by excluding pts with rapidly progressive disease. Using a decision analysis model, benefits and risks of a neoadjuvant PC strategy were evaluated. Methods: We developed a Markov model to compare life expectancy (LE) in a simulated cohort of 10,000 resectable PC pts who were randomized to strategies of 1) attempted pancreatic resection, recovery and postop CRT; or 2) neoadjuvant CRT, restaging and surgery in the absence of progression. Probabilities were calculated using published data including median survival, assuming exponential survival decreases. Additional analyses used quality-adjusted life expectancy (QALE). Results: Neoadjuvant strategy offered a survival benefit over up-front surgical strategy (LE 20.1 vs. 18.9 mos). Sensitivity analyses were used to assess the importance of progression during preop CRT; when progression > 39.5%, upfront surgery became favored (in order to minimize Type I error, this analysis did not adjust for the fact that pts who progress on preop CRT would likely be early recurrences if randomized to upfront surgery). In an adapted model compensating for quality of life including surgery impact, neoadjuvant CRT proved increasingly superior to upfront surgery (QALE 19.8 vs. 16.4 mos). In a sensitivity analysis to test the potential effect of neoadjuvant regimens with different efficacy, neoadjuvant was favored provided that median survival > 21.5 mo after diagnosis among pts who received neoadjuvant + resection; the advantage of neoadjuvant improved as this median survival increased. Conclusions: Decision analysis modeling suggests that a neoadjuvant CRT strategy offers improved survival compared to a postoperative CRT strategy for resectable PC. Adjusting for quality of life increases the potential neoadjuvant advantage. Importantly, as survival duration increases, the neoadjuvant strategy is increasingly favored – suggesting an added value to neoadjuvant treatment as improved systemic therapies are developed. No significant financial relationships to disclose.